These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27620924)

  • 1. The importance of surveillance: Group W meningococcal disease outbreak response and control in England.
    Campbell H; Ladhani S
    Int Health; 2016 Nov; 8(6):369-371. PubMed ID: 27620924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study.
    Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME; Ladhani SN
    Lancet Child Adolesc Health; 2022 Feb; 6(2):96-105. PubMed ID: 34883094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study.
    Knol MJ; Hahné SJM; Lucidarme J; Campbell H; de Melker HE; Gray SJ; Borrow R; Ladhani SN; Ramsay ME; van der Ende A
    Lancet Public Health; 2017 Oct; 2(10):e473-e482. PubMed ID: 29253430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited Impact of Adolescent Meningococcal ACWY Vaccination on Neisseria meningitidis Serogroup W Carriage in University Students.
    Oldfield NJ; Green LR; Parkhill J; Bayliss CD; Turner DPJ
    J Infect Dis; 2018 Jan; 217(4):608-616. PubMed ID: 29155998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England.
    Ladhani SN; Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Clark SA; Lucidarme J; Borrow R; Ramsay ME
    Clin Infect Dis; 2021 Oct; 73(7):e1661-e1668. PubMed ID: 32845996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies.
    Booy R; Gentile A; Nissen M; Whelan J; Abitbol V
    Hum Vaccin Immunother; 2019; 15(2):470-480. PubMed ID: 30296197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
    Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
    Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enter B and W: two new meningococcal vaccine programmes launched.
    Ladhani SN; Ramsay M; Borrow R; Riordan A; Watson JM; Pollard AJ
    Arch Dis Child; 2016 Jan; 101(1):91-5. PubMed ID: 26672098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of invasive meningococcal disease in university students in England and optimal strategies for protection using MenACWY vaccine.
    Mandal S; Campbell H; Ribeiro S; Gray S; Carr T; White J; Ladhani SN; Ramsay ME
    Vaccine; 2017 Oct; 35(43):5814-5818. PubMed ID: 28928076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.
    Bousema JC; Ruitenberg J
    Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017.
    Krone M; Gray S; Abad R; Skoczyńska A; Stefanelli P; van der Ende A; Tzanakaki G; Mölling P; João Simões M; Křížová P; Emonet S; Caugant DA; Toropainen M; Vazquez J; Waśko I; Knol MJ; Jacobsson S; Rodrigues Bettencourt C; Musilek M; Born R; Vogel U; Borrow R
    Euro Surveill; 2019 Apr; 24(14):. PubMed ID: 30968827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.
    Carr JP; MacLennan JM; Plested E; Bratcher HB; Harrison OB; Aley PK; Bray JE; Camara S; Rodrigues CMC; Davis K; Bartolf A; Baxter D; Cameron JC; Cunningham R; Faust SN; Fidler K; Gowda R; Heath PT; Hughes S; Khajuria S; Orr D; Raman M; Smith A; Turner DPJ; Whittaker E; Williams CJ; Zipitis CS; Pollard AJ; Oliver J; Morales-Aza B; Lekshmi A; Clark SA; Borrow R; Christensen H; Trotter C; Finn A; Maiden MC; Snape MD;
    Clin Microbiol Infect; 2022 Dec; 28(12):1649.e1-1649.e8. PubMed ID: 35840033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
    Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
    JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
    Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
    Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.